Screening aims primarily to identify PC in asymptomatic individuals, with digital rectal examination (DRE) and blood prostate-specific antigen (PSA) testing serving as foundational diagnostic tools [2]. The gene discussed is KLK3; the disease is pachyonychia congenita.